[Double blind comparison of the antidepressives viloxazine and imipramine (author's transl)].
In a double blind trial in 88 patients, 71 of whom were included in the fin al evaluation, viloxazine (Vivalan ICI) showed an effectiveness corresponding to imipramine. Both antidepressives show properties for lysis of depression and improvement of mood, the target symptom is vitally depressive disturbance of mood. There was clear improvement of depression, anxieties, restlessness, loss of initiative and activity as well as pain syndromes in psychosomatic disorders. In cases of psychomotor inhibition viloxazine was superior to the older drug. Effectiveness of viloxazine commenced rapidly as demonstrated by control assessment after 10-14 days. Results improved further in a second equally long treatment period. Tolerance of viloxazine was superior to imipramine.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy; D011595:Psychomotor Agitation; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D014745:Viloxazine / Q000009:adverse effects / Q000627:therapeutic use*
D009025:Morpholines; D014745:Viloxazine; D007099:Imipramine
Doppelblindvergleich der Antidepressiva Viloxazin und Imipramin.